Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant

Poly (ADP-ribose) polymerase (PARP) inhibitors have been approved in malignancies associated with germline BRCA1 or BRCA2 pathogenic variants, such as breast, ovarian, prostate, and pancreatic cancer. In malignancies not associated with germline BRCA1 or BRCA2 pathogenic variants, the therapeutic re...

Descripción completa

Detalles Bibliográficos
Autores principales: Soon Jian Hao, Jonathan, Hoai, Chan Sock, Weng, Daniel Tan Shao, Ngeow, Joanne, Chiang, Jianbang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2022
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808557/
https://www.ncbi.nlm.nih.gov/pubmed/36577523
http://dx.doi.org/10.1101/mcs.a006223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808557/
https://www.ncbi.nlm.nih.gov/pubmed/36577523
http://dx.doi.org/10.1101/mcs.a006223

Ejemplares similares